Trial Profile
Assessment of Physical Functioning and Handling of Spiolto Respimat in Patients With Chronic Obstructive Pulmonary Disease (COPD) Requiring Long-acting Dual Bronchodilation in Routine Clinical Practice
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Oct 2018
Price :
$35
*
At a glance
- Drugs Olodaterol/tiotropium bromide (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 21 Apr 2017 Status changed from active, no longer recruiting to completed.
- 21 Feb 2017 Planned End Date changed from 1 Feb 2017 to 1 Mar 2017.
- 21 Feb 2017 Status changed from recruiting to active, no longer recruiting.